That Business Show 2.0 is a daily online videocast and podcast that speaks with entrepreneurs and business professionals about business building tips and aims to give the listeners tools, tips and resources to grow their own business. Find it online each morning at www.thatbusinessnetwork.com from 9am to 10am M-F EST.
At 8am, we welcomed Dennise Ondina, Executive Director of the Compass Brain Injury Center. She was joined in studio by her son Ian as well who was the inspiration of this non-profit after suffering a traumatic brain injury while riding an ATV at age 19. After months of treatments and surgeries, in which he was not expected to survive at one point), Ian pulled through but had to re-learn many things including who his family was and how to do many basic things. Disappointed by the lack of support after leaving the care units, Dennise saw the need for a support group for those impacted by traumatic brain injuries and launched Compass Brain Injury Center. Dennise is in the start-up phase of the organization and is looking for help and guidance from others. They are currently holding support group meetings for victims and caregivers and their first board of directors meeting is in September. If you have any way to help, please reach out to Dennise, phone is 727-204-2723 and website is www.compassbraininjurycenter.org. Today Ian has recovered much of what he lost but still struggles and needs assistance. He speaks briefly on the program to share personally his challenges and lets us know that he recently returned to College and has achieved a straight A report card. Your support will help him and many others in the same situation.
Closing out the week and program was Dr. Glynn Wilson, CEO of TapImmune, an Immuno-oncology Company developing T-cell vaccines for the treatment of breast and ovarian cancer. The vaccine works by stimulating the body’s own immune system is now the most promising approach for treating cancer. TapImmune now has the worldwide exclusive license on two vaccine technologies from the Mayo Clinic: A folate receptor alpha vaccine (TPIV 200) and a HER2neu vaccine (TPIV 110) and both technologies were discovered by Dr Keith Knutson of the Mayo Clinic. Both vaccines have completed Phase I clinical trials and were shown to be safe and well tolerated and to produce robust immune responses in over 90% of patients treated. The Company has received Orphan Drug designation and Fast Track status from the FDA for ovarian cancer and their HER2neu vaccine will enter Phase II clinical trials early in 2017. Dr. Wilson has been personally affected by these cancers having lost his wife to the disease. We share a great discussion on this segment about TapImmune and cancer in general and more can learned at www.tapimmune.com and you can follow the results of the clinical trials at www.clinicaltrials.gov!
Filetype: MP3 - Size: 17.69MB - Duration: 51:31 m (48 kbps 16000 Hz)
From the admin area you can customize this box. For instance you can add Widgets and Buttons
You can optionally disable the freebox if you don't need it.